- Associated Press•4 months ago
On a per-share basis, the Alpharetta, Georgia-based company said it had a loss of 14 cents. The drug development company posted revenue of $5.3 million in the period. In the final minutes of trading on ...
- PR Newswire•6 months agoShareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of Rockwell Medical, Inc., AAC Holdings, Inc., Dr. Reddy's Laboratories Ltd. and Biota Pharmaceuticals, Inc,; Encourages Investors to Contact the Firm for Information Concerning Their Legal Rights
Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Rockwell Medical, Inc. (RMTI) and certain of its officers and directors. On September 9, 2015, Rockwell Medical disclosed the U.S. commercial launch of Triferic, a FDA approved iron product designed to replace iron and preserve hemoglobin in hemodialysis patients in the United States.
- Zacks Small Cap Research•6 months ago
By Anita Dushyanth, PhD NASDAQ:BOTA Following the successful Single Ascending Dose (SAD) study, Biota (NASDAQ:BOTA) completed the Phase 1 multiple ascending dose (MAD) study in the beginning of 2016. The ...
** SEE<AVIR> (BOTA)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|